Comparative Pharmacology
Head-to-head clinical analysis: AVELOX versus TROVAN PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVELOX versus TROVAN PRESERVATIVE FREE.
AVELOX vs TROVAN PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.
Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, thereby inhibiting bacterial DNA replication and transcription.
400 mg orally or intravenously once daily for 7 to 14 days depending on infection severity.
200 mg intravenously once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10-14 hours) in healthy adults, allowing once-daily dosing. May be prolonged in patients with renal impairment.
Terminal elimination half-life is approximately 10–13 hours in patients with normal renal function; prolonged in renal impairment.
Renal (approximately 45-60% as unchanged drug and metabolites) and biliary/fecal (approximately 20-30% as unchanged drug and metabolites). Total recovery in urine and feces accounts for >96% of the dose.
Renal excretion accounts for approximately 90% of elimination, with ~50% as unchanged drug. Fecal/biliary excretion accounts for the remaining ~10%.
Category C
Category C
Antibiotic (Fluoroquinolone)
Antibiotic (Fluoroquinolone)